- Home
- LXEO vs ADCT Comparison
LXEO vs ADCT Comparison
Compare LXEO & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEO
- ADCT
- Stock Information
- Founded
- LXEO 2017
- ADCT 2011
- Country
- LXEO United States
- ADCT Switzerland
- Employees
- LXEO N/A
- ADCT N/A
- Industry
- LXEO
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- LXEO
- ADCT Health Care
- Exchange
- LXEO Nasdaq
- ADCT Nasdaq
- Market Cap
- LXEO 314.1M
- ADCT 285.2M
- IPO Year
- LXEO 2023
- ADCT 2020
- Fundamental
- Price
- LXEO $6.24
- ADCT $1.98
- Analyst Decision
- LXEO Strong Buy
- ADCT Strong Buy
- Analyst Count
- LXEO 7
- ADCT 5
- Target Price
- LXEO $22.71
- ADCT $7.33
- AVG Volume (30 Days)
- LXEO 623.4K
- ADCT 437.2K
- Earning Date
- LXEO 11-13-2024
- ADCT 11-07-2024
- Dividend Yield
- LXEO N/A
- ADCT N/A
- EPS Growth
- LXEO N/A
- ADCT N/A
- EPS
- LXEO N/A
- ADCT N/A
- Revenue
- LXEO N/A
- ADCT $70,717,000.00
- Revenue This Year
- LXEO N/A
- ADCT $6.66
- Revenue Next Year
- LXEO N/A
- ADCT $16.38
- P/E Ratio
- LXEO N/A
- ADCT N/A
- Revenue Growth
- LXEO N/A
- ADCT N/A
- 52 Week Low
- LXEO $5.77
- ADCT $0.69
- 52 Week High
- LXEO $22.33
- ADCT $6.04
- Technical
- Relative Strength Index (RSI)
- LXEO 28.99
- ADCT 25.90
- Support Level
- LXEO $5.77
- ADCT $1.89
- Resistance Level
- LXEO $11.72
- ADCT $3.06
- Average True Range (ATR)
- LXEO 0.85
- ADCT 0.23
- MACD
- LXEO -0.19
- ADCT -0.11
- Stochastic Oscillator
- LXEO 5.71
- ADCT 8.83
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.